Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Share-based Compensation (2016 - 2025)

Capricor Therapeutics has reported Share-based Compensation over the past 15 years, most recently at $3.8 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $3.8 million for Q4 2025, up 67.33% from a year ago — trailing twelve months through Dec 2025 was $17.0 million (up 73.76% YoY), and the annual figure for FY2025 was $17.0 million, up 73.76%.
  • Share-based Compensation for Q4 2025 was $3.8 million at Capricor Therapeutics, down from $12.9 million in the prior quarter.
  • Over the last five years, Share-based Compensation for CAPR hit a ceiling of $12.9 million in Q3 2025 and a floor of -$5.2 million in Q2 2025.
  • Median Share-based Compensation over the past 5 years was $1.7 million (2023), compared with a mean of $2.1 million.
  • Peak annual rise in Share-based Compensation hit 527.36% in 2025, while the deepest fall reached 342.68% in 2025.
  • Capricor Therapeutics' Share-based Compensation stood at $780150.0 in 2021, then skyrocketed by 47.18% to $1.1 million in 2022, then surged by 62.14% to $1.9 million in 2023, then grew by 23.31% to $2.3 million in 2024, then skyrocketed by 67.33% to $3.8 million in 2025.
  • The last three reported values for Share-based Compensation were $3.8 million (Q4 2025), $12.9 million (Q3 2025), and -$5.2 million (Q2 2025) per Business Quant data.